Is Our Investment Getting Us the Health Results We're Paying For?
This article was originally published in RPM Report
Executive Summary
Pfizer CEO Jeff Kindler sees theenvironment for pharma continuing to evolve at a fast pace. In a broad, direct speech to the leading PBM trade group he notes that pharm companiesare habving to adapt to a new world in which they do not exclusively control the information about their products. The changes will force pharm to pursue new opportunites, such as product differentiation through clinical services.
You may also be interested in...
REMS 2.0: FDA Refining New Drug Safety Tools
FDA’s new post-marketing risk management authorities are receiving much more public attention in the context of the Avandia decision…but use of the REMS is actually declining. As FDAAA turns 3, it is clear that REMS are going through some growing pains. The new tools will be refined—but they are definitely here to stay.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.